Differential adaptive changes on serotonin and noradrenaline transporter (cas 136253-20-8)s in a rat model of peripheral neuropathic pain

Add time:09/07/2019    Source:sciencedirect.com

Serotonin and noradrenaline reuptake inhibitors have shown to produce antinociceptive effects in several animal models of neuropathic pain. In the present work, we have analyzed the density of brain and spinal serotonin and noradrenaline transporters (5-HTT and NAT) in a rat model of neuropathic pain, the spinal nerve ligation (SNL). Quantitative autoradiography revealed a significant decrease in the density of 5-HTT ([3H]citalopram binding) at the level of the lumbar spinal cord following 2 weeks of neuropathic surgery (lamina V, −40%: 6.01 ± 0.64 nCi/mg tissue in sham-animals vs 3.59 ± 1.56 in SNL-animals; lamina X, −30%: 9.10 ± 2.00 vs 6.40 ± 1.93 and lamina IX, −22%: 12.01 ± 2.41 vs 9.42 ± 1.58). By contrast, NAT density ([3H]nisoxetine binding) was significantly increased (lamina I–II, +34%: 2.20 ± 0.45 vs 2.96 ± 0.65; lamina V, +57%: 1.34 ± 0.28 vs 2.11 ± 0.66; and lamina IX, +58%: 2.39 ± 0.71 vs 3.78 ± 1.10). At supraspinal structures, SNL induced adaptive changes only in the density of 5-HTT (septal nuclei, +33%: 10.18 ± 2.03 vs 13.53 ± 1.14; CA3 field of hippocampus, +18%: 6.94 ± 1.01 vs 8.21 ± 0.81; paraventricular thalamic nucleus, +21%: 15.18 ± 1.88 vs 18.35 ± 2.08; lateral hypothalamic area, +40%: 12.68 ± 1.90 vs 17.8 ± 2.55; ventromedial hypothalamic nuclei, +19%: 7.16 ± 0.92 vs 8.55 ± 0.40; and dorsal raphe nucleus, +15%: 35.22 ± 3.88 vs 40.68 ± 3.11). Thus, we demonstrate, in the SNL model of neuropathic pain, the existence of opposite changes in the spinal expression of 5-HTT (down-regulation) and NAT (up-regulation), and the presence of supraspinal adaptive changes (up-regulation) only on 5-HTT density. These findings may help understanding the pathogeny of neuropathic pain and the differential analgesic action of antidepressants targeting 5-HTT and/or NAT transporters.

We also recommend Trading Suppliers and Manufacturers of noradrenaline transporter (cas 136253-20-8). Pls Click Website Link as below: cas 136253-20-8 suppliers

Prev:Short communicationAltered cardiac gene expression of noradrenaline enzymes, transporter and β-adrenoceptors in rat model of rheumatoid arthritis
Next:Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: Analysis of serotonin and noradrenaline transporter (cas 136253-20-8) binding)